Previous 10 | Next 10 |
2023-06-26 10:08:32 ET Gainers: MoonLake Immunotherapeutics ( MLTX ) +69% . Chemomab Therapeutics ( CMMB ) +33% . Acelyrin ( SLRN ) +22% . ORIC Pharmaceuticals ( ORIC ) +15% . Losers: Avalo Therapeutics ( AVTX ) -85% . Fi...
2023-06-26 08:22:19 ET Avalo Therapeutics ( AVTX ) -89% announces topline data from phase 2 PEAK trial for AVTX-002 (quisovalimab) in patients with non-eosinophilic asthma. FibroGen ( FGEN ) -76% late-stage trial for lung disease candidate fails . Lulu's Fa...
- Study did not meet the primary endpoint - Pamrevlumab was generally safe and well tolerated - ZEPHYRUS-2 Phase 3 study will be discontinued - Company to implement plan to extend cash runway into 2026 SAN FRANCISCO, June 26, 2023 (GL...
2023-06-23 15:00:37 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
Study did not meet the primary endpoint Pamrevlumab was generally safe and well tolerated Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023 SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. ...
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following investor conferences: Jefferies Global Healthcare Conference taking place in New York, NY on T...
NEW ORLEANS, June 06, 2023 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On July 15, 20...
2023-06-05 15:27:08 ET Summary FibroGen, Inc. results from the phase 3 LELANTOS-1 study, using pamrevlumab for the treatment of patients with non-ambulatory Duchenne Muscular Dystrophy, are expected any day now in Q2 of 2023. Results from the phase 3 LELANTOS-2 study, using pamrev...
2023-06-02 17:34:13 ET FibroGen ( NASDAQ: FGEN ) stock has been upgraded to buy by Stifel ahead of the expected release of data from two Phase 3 studies for its drug pamrevlumab. Stifel said in its note dated June 1 that the company was fast approaching two "critical" data reado...
2023-06-02 15:00:55 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...